Obefazimod

An immunomodulatory drug for ulcerative colitis

Obefazimod
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Obefazimod is an investigational drug being developed for the treatment of ulcerative colitis, a form of inflammatory bowel disease (IBD). It is known for its immunomodulatory properties, which help in reducing inflammation in the colon.

Mechanism of Action

Obefazimod works by modulating the immune response, specifically targeting the immune system pathways involved in inflammation. It acts on the G protein-coupled receptors (GPCRs) to alter the signaling pathways that lead to the production of pro-inflammatory cytokines. This action helps in reducing the inflammation and tissue damage associated with ulcerative colitis.

Clinical Development

Obefazimod is currently undergoing clinical trials to evaluate its efficacy and safety in patients with moderate to severe ulcerative colitis. The trials are designed to assess the drug's ability to induce and maintain remission in patients who have not responded adequately to conventional therapies.

Pharmacokinetics

The pharmacokinetic profile of Obefazimod includes its absorption, distribution, metabolism, and excretion. It is administered orally and is absorbed in the gastrointestinal tract. The drug is metabolized in the liver and excreted primarily through the kidneys.

Side Effects

As with any medication, Obefazimod may cause side effects. Common side effects observed in clinical trials include headache, nausea, and fatigue. Serious side effects are rare but may include liver function abnormalities and increased risk of infections due to its immunosuppressive action.

Potential Benefits

The potential benefits of Obefazimod include its ability to provide relief from the symptoms of ulcerative colitis, such as abdominal pain, diarrhea, and rectal bleeding. By reducing inflammation, it may also help in healing the lining of the colon and improving the quality of life for patients.

Research and Future Directions

Research on Obefazimod is ongoing, with studies focusing on its long-term safety and effectiveness. Future directions may include exploring its use in other inflammatory conditions and optimizing its dosing regimen to maximize therapeutic outcomes.

Related Pages

• Ulcerative colitis
• Inflammatory bowel disease
• Immunomodulatory drugs
• G protein-coupled receptor